











































Risk factors for breast cancer development by tumor
characteristics among women with benign breast disease
Citation for published version:
Figueroa, JD, Gierach, GL, Duggan, MA, Fan, S, Pfeiffer, RM, Wang, Y, Falk, RT, Loudig, O, Abubakar, M,
Ginsberg, M, Kimes, TM, Richert-Boe, K, Glass, AG & Rohan, TE 2021, 'Risk factors for breast cancer
development by tumor characteristics among women with benign breast disease', Breast Cancer Research,
vol. 23, no. 1, pp. 34. https://doi.org/10.1186/s13058-021-01410-1
Digital Object Identifier (DOI):
10.1186/s13058-021-01410-1
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
 1 
Risk factors for breast cancer development by tumor characteristics among women with benign 
breast disease 
 
Jonine D. Figueroa1,2,3*, Gretchen L. Gierach1*, Máire A. Duggan4, Shaoqi Fan1, Ruth M. Pfeiffer1, 
Yihong Wang5, Roni T. Falk1, Olivier Loudig6, Mustapha Abubakar1, Mindy Ginsberg7, Teresa M. Kimes8, 
Kathryn Richert-Boe8, Andrew G. Glass, MD8Φ, Thomas E. Rohan7. 
 
*Contributed equally 
1NationalCancer Institute, Bethesda, USA; 2The Usher Institute and 3CRUK Edinburgh Centre, The 
University of Edinburgh, UK; 4University of Calgary, Canada; 5Warren Alpert Medical School of Brown 
University, USA; 6 Center for Discovery and Innovation (CDI), Hackensack Meridian Health, Nutley, NJ 
7AlbertEinstein College of Medicine, NY, USA; 8Kaiser Permanente Center for Health Research, Portland, 
OR, USA; ΦDeceased.  
 
 
Address for correspondence: 
Jonine Figueroa 
Usher Institute, University of Edinburgh 
Old Medical School, Teviot Place, Edinburgh, EH8 9AG 
CRUK Edinburgh Centre, Institute of Genetics and Molecular Medicine 




Albert Einstein College of Medicine 
Jack and Pearl Resnick Campus 
1300 Morris Park Avenue 
Belfer Building, Room 1301 
Bronx, NY 10461 









Background: Among women diagnosed with invasive breast cancer, 30% have a prior diagnosis of benign 
breast disease (BBD). Thus, it is important to identify factors among BBD patients that elevate invasive 
cancer risk. In the general population, risk factors differ in their associations by clinical pathologic features; 
however, whether women with BBD show etiologic heterogeneity in the types of breast cancers they 
develop remains unknown.   
Methods: Using a nested case-control study of BBD and breast cancer risk conducted in a community 
healthcare plan (Kaiser Permanente Northwest), we assessed relationships of histologic features in BBD 
biopsies and patient characteristics with subsequent breast cancer risk and tested for heterogeneity of 
associations by estrogen receptor (ER) status, tumor grade and size. The study included 514 invasive breast 
cancer cases (median follow-up of 9 years post-BBD diagnosis) and 514 matched controls, diagnosed with 
proliferative or non-proliferative BBD between 1971-2006, with follow-up through mid-2015. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were obtained using multivariable polytomous logistic 
regression models.  
Results: Breast cancers were predominantly ER-positive (86%), well- or moderately-differentiated (73%), 
small (74% <20mm) and stage I/II (91%). Compared to patients with non-proliferative BBD, proliferative 
BBD with atypia conferred risk for ER-positive (OR=5.48, 95%CI=2.14-14.01) with only one ER-negative 
case); p-heterogeneity=0.45. Presence of columnar cell lesions (CCLs) at BBD diagnosis was associated 
with a 1.5-fold increase in risk of both ER-positive and ER-negative tumors, with a 2-fold increase 
(95%CI=1.21-3.58) observed among postmenopausal women (56%), independent of proliferative BBD 
status with and without atypia. We did not identify statistically significant differences in risk factor 
associations by tumor grade or size.  
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Conclusion: Most tumors that developed after a BBD diagnosis in this cohort were highly treatable low-
stage ER-positive tumors. CCL in BBD biopsies may be associated with moderately increased risk, 
independent of BBD histology, and irrespective of ER status.  
 





It is well established that benign breast diseases (BBDs) increase risk of breast cancer in women 
[1]. In the U.S., biopsy-confirmed BBD diagnoses are 4-times more common than invasive breast cancers, 
affecting ~1 million women annually. BBDs include a range of pathologies with approximately 30% 
comprising proliferative BBD lesions (PDWA, proliferative disease i.e., without atypia) and 65% 
encompassing non-proliferative benign lesions [2, 3]. Proliferative BBD with atypia (atypical hyperplasia ) 
represent 3-4% of BBD diagnoses, have been associated with a 4-5 fold increased breast cancer (BC) risk 
[3, 4], and considered as an indication for possible chemoprevention [5].   
Since women diagnosed with BBD comprise a large proportion of future breast cancer cases 
(~30%), it is important to identify factors associated  with subsequent BC [3]. Having undergone a 
clinically-indicated breast biopsy, women with BBD provide the opportunity for evaluation of whether 
histopathologic features increase BC risk independently of other patient characteristics. Providing accurate 
invasive BC risk estimates for BBD patients could improve clinical management of this large group of 
women, including  determination of whether watchful waiting, surgery, or chemoprevention should be 
offered [3]. In a model that predicted overall BC risk for BBD patients, key risk factors were parity/age at 
first birth and family history of breast cancer, as well as histologic features, including columnar cell lesions 
(CCLs), radial scars, sclerosing adenosis, and lobular involution [6]. Within the Kaiser BBD study, 
previous analyses examined associations of lifestyle, reproductive and pathologic characteristics that are 
associated with subsequent risk of breast cancer [7],[8]; however, whether risks associated with these 
factors are similar or vary by the characteristics of the tumors diagnosed among BBD patients is not well 
understood and has not been previously assessed.  
Breast cancer is a heterogeneous disease, with data strongly supporting different associations of risk 
factors such as parity and genetic susceptibility loci by tumor subtypes defined by hormone receptor status 
and other clinical/pathologic features [9-12]. Whether similar etiologic heterogeneity exists for breast 
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cancer arising in BBD patients is unknown, and to date very few cohort studies have been able to assess 
this hypothesis [7, 13, 14].  We therefore assessed patient and BBD histopathological features associated 
with BC risk and evaluated whether relationships varied by tumor characteristics. 
Methods: 
Study population 
 We utilized data from a previously designed case-control study of BBD and breast cancer risk [7], 
nested within a BBD cohort from Kaiser Permanente Northwest (KPNW), which provides medical care for 
approximately ½ million members located in Southwest Washington and Northwest Oregon. The source 
population was comprised of women who had biopsy-confirmed BBD diagnosed between August 3, 1971 
and December 31, 2006 (N=15,395; age range 21-85 years), one control had a BBD diagnosis in 2012. 
Invasive breast cancer diagnoses were obtained through record linkage with the KPNW Tumor Registry, as 
previously described [7].  Briefly, cases were defined as women diagnosed with invasive breast cancer at 
least one year after BBD diagnosis, and with no prior history of in situ lesions. The follow-up rate for the 
KPNW Tumor Registry since its inception in 1960 has been excellent, accounting for 98% of patients 
(living or dead) even if they are no longer health plan members. Controls were women with a biopsy for 
BBD who were alive but had not developed breast cancer during the same follow-up calendar period as that 
for the corresponding cases. For each case, a control case was randomly selected using risk-set sampling 
with replacement, matched at age at diagnosis of BBD (±1 year) and, implicitly, given the risk-set 
sampling, on duration of membership of KPNW [15]. In addition, each control was required not to have 
undergone a mastectomy before the date of diagnosis of breast cancer for her matched case. If a selected 
control did not have breast tissue for evaluation or had no risk factor information, a replacement control 
was selected. There were 514 cases and 514 matched controls available for these analyses. 
 
Tumor characteristics  
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We obtained information on the following variables from the KPNW Tumor Registry: date of invasive 
breast cancer diagnosis, date of death, tumor histology and behavior using ICD-O coding, grade, AJCC 
clinical staging variable, tumor size, lymph node status. Immunohistochemistry (IHC) data on key markers 
were obtained for ER (which has been measured on cases since the mid-1970s), PR (first measured in 
1983) and HER2 status (first measured in 1988). The percentage of tumors analyzed for ER status 
increased from 0% in 1980, to 18% in 1989, 54% in 1994, and 85% in 2006; HER2 status was available on 
43% of tumors until 2001 and on 68% from 2002 onward.  
 
Risk factor information 
 Risk factor data were captured using routine medical records, which include information on clinic 
visits, prescriptions, operations and laboratory testing. These data were linked using the KPNW unique 
health record numbers to identify each individual member. From these records, data were available for 
various exposures. We focused on established or suspected breast cancer risk factors, specifically: family 
history of breast cancer, age at menarche, parity, age at first birth, body mass index (BMI) at benign 
biopsy, menopausal status, and menopausal hormone use. KPNW has a well characterized mammography 
screening program and by 1993 more than 75% of women over 45 had had a screening mammogram [16]. 
For this reason, we also report characteristics stratified by this date (Supplemental Table 1). 
BBD histology was assessed according to the Page classification criteria [1], as follows: 
proliferative disease with atypia (ADH), if atypical hyperplasia (either ductal or lobular) was present; 
proliferative disease without atypia, if epithelial hyperplasia without atypia (either moderate or florid) 
OR fibroadenoma (either complex-no atypia or complex-atypia) OR sclerosing adenosis OR radial scar OR 
papilloma was present; non-proliferative, if non-proliferative lesion (either cysts, fibrosis, or apocrine 
metaplasia) OR mild epithelial hyperplasia without atypia OR fibroadenoma was present. Pathologist 
assessment of biopsies was blinded to case-control status as previously described [8]. CCL pathology and 
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terminal duct lobular unit (TDLU) involution status were additionally ascertained on digitized BBD H&E 
images using the Aperio Scanscope system. Furthermore, as involution status is not typically reported in 
clinical pathology, we obtained more detailed semi-quantitative measures of TDLU involution previously 
reported to be associated with breast cancer risk among BBD patients (see Supplemental Methods).   
 
Multiple imputation  
We used multiple imputation to impute missing data for risk factors. The largest amount of 
missingness (21%) was seen for the age at menarche variable (see Supplemental Methods and Appendix A). 
We did not impute missing data on MHT use, as the % missingness was too large (45%) to allow for stable 
imputation. All variables that were correlated or associated with the outcome variables or that were 
potentially related to the missingness of other imputed variables were included in the imputation models (see 
Supplemental Methods)[17, 18]. Variables were imputed as continuous and later categorized for further 
analyses. Multiple imputations were performed using IVEware (0.3 version, 
https://www.src.isr.umich.edu/software/iveware-documentation/iveware-with-sas/). Details of imputation 
steps are delineated in a flow chart (Supplementary Figure 1 and Appendix A in Supplemental Material). 
All calculations presented in this paper were conducted for 5 imputed datasets separately; estimates from the 
different imputed datasets were combined and variances were computed using Rubin’s formula as 
implemented in SAS 9.4, PROC MIANALYZE. 
 
Statistical analysis 
 Descriptive statistics of demographic and tumor characteristics by calendar year of BBD diagnosis 
and age at breast cancer diagnosis were assessed using Chi-squared or Fisher’s exact tests.  Conditional 
logistic regression and unconditional logistic models adjusted for the matching factors yielded similar 
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estimates (Supplemental Table 2). We therefore present odds ratios (ORs) and 95% confidence intervals 
(CIs) for demographic, reproductive or tissue factors (explanatory variables) for overall breast cancer risk 
from unconditional regression models. The unconditional logistic regression models included matching 
factors, as well as continuous age at BBD diagnosis and follow-up period from BBD diagnosis to breast 
cancer diagnosis; other key risk factors included in the models were: family history of breast cancer in 1st 
degree relatives, history of bilateral oophorectomy, and parity. For the main analysis to determine 
associations by breast cancer subtype (comparing ER, PR and HER2 status or clinicopathologically defined 
subtypes), we used polytomous logistic regression models adjusted for matching factors and using the same 
variables as for the overall BC model. Heterogeneity between factors was assessed using polytomous 
logistic regression analyses restricted to cases (case-only analyses) with the tumor characteristics (ER, 
tumor size and grade) as the outcome variable. Models were also stratified by menopausal status.  A p<0.05 




Tumor characteristics by patient characteristics, age at breast cancer diagnosis and BBD calendar year at 
diagnosis 
Characteristics of the BBD patients are detailed in Supplemental Tables 1 and 2. The median age 
of BBD diagnosis was 51.5 years and over 60% of cases were diagnosed between 1980-1999. As 
mammography screening became more common after 1993, we observed an increased frequency of 
proliferative disease without atypia (38.5 vs 27.6%) and with atypia (7.3 vs 4.0%, Supplemental Table 1) 
subsequent to 1993. We also observed increased detection of prevalent breast cancer and a stage shift, with 
a 12% increase in diagnosed stage I tumors after 1993 (Supplemental Table 1). The median follow-up 
between BBD and breast cancer diagnosis was 9.0 years (IQR=4.4, 15.8 years), with a median age at breast 
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cancer diagnosis of 62.7 years.  Descriptive characteristics of the BBD patients subsequently diagnosed 
with breast cancer, overall, and stratified by age at breast cancer diagnosis, are presented in Table 1. Most 
cases were older than 50 years (87%) at diagnosis. Breast cancers were mostly diagnosed from 1996-2005, 
and 55% of cases were diagnosed within 10 years of their initial BBD diagnosis.  
 
Tumors diagnosed in this population were predominantly small (71.6% <20mm), well or 
moderately differentiated (73.6%), ER-positive (85.9%), PR-positive (71.2%), HER2-negative (79.4%), 
lymph node negative (73.6%), and of ductal histology (83.5%). The invasive cases were overwhelmingly 
of low stage, with <10% of cases being diagnosed as stage III or IV. As expected, ER status differed 
significantly by age at breast cancer diagnosis, with a higher proportion (24.5%) of ER-negative breast 
cancers diagnosed among women <50 compared to those older than 50 (12.8%). We also assessed whether 
there were differences in tumor characteristics by calendar period before and during/after 1993 [16]. Of the 
tumor characteristics evaluated, HER2 status showed a statistically significant difference by BBD diagnosis 
before and during/after 1993, with a higher proportion of HER2 negative cases diagnosed after 1993 
compared to prior years (84.2 vs 73.9%, Supplemental Table 1). After 1993 significantly more of the 
tumors occurred among women >50 years of age, were of smaller size (10-20mm;44.4% during/after 1993 
vs 34.8% before 1993), and had no or mild involution (48.93% during/after 1993 vs 36.56% before 1993, 
Supplemental Table 1). Histologic grade data were not routinely reported prior to 1993.  
 
Breast cancer risk factors among women with BBD 
Association results for all cases combined for established risk factors, including BBD 
characteristics, are shown in Supplemental Table 2. We found that younger age at first full term birth and 
history of bilateral oophorectomy were inversely associated with breast cancer risk, whereas positive 
family history of breast cancer in a 1st degree relative, increasing severity of BBD histology and presence 
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of CCL at BBD diagnosis were associated with increased breast cancer risk (Supplemental Table 2).  A 
representative image of CCL is shown in Figure 1. CCL with atypia, also known as flat epithelial atypia, is 
a more severe lesion that has been suggested to be associated with increased risk of breast cancer [3]; 
however, we were unable to assess this association in the present study as only 2 controls and 1 case had 
flat epithelial atypia. Lobular involution, which has been proposed in other BBD patient populations as a 
key risk factor for subsequent breast cancer [6, 19], was weakly inversely associated with breast cancer risk 
in our population [complete vs no involution, OR (95%CI) = 0.89 (0.65, 1.24)]. Neither radial scar nor 
sclerosing adenosis conferred a significant risk among those with proliferative BBD disease (data not 
shown).   
 
Breast cancer risk by ER status among women with BBD 
Risk associations by ER status for patient characteristics and histologic features of BBD are 
presented in Table 2. Most tumors were ER-positive, which limited power to detect heterogeneity; as a 
result, patterns of association observed for overall invasive breast cancer were generally consistent with 
those observed for ER-positive breast cancer risk. Having an age at first birth <30 years was associated 
with reduced risk of ER-positive (OR=0.69, 95%CI=0.49-0.98), but not ER-negative (OR=1.08, 95% 
CI=0.51-2.30) breast cancer (p-heterogeneity=0.24). Compared with patients with non-proliferative BBD, 
those with proliferative BBD with atypia had a greater than five-fold increased risk for ER-positive disease 
(OR=5.48, 95% CI=2.14-14.01). There was only one ER-negative case, hence, too few cases to provide a 
reliable estimate in this subgroup. After accounting for BBD histology, the presence of CCLs at BBD 
diagnosis was associated with a 1.5-fold increased risk for both ER-positive (95% CI=1.03-2.29) and ER-
negative (95% CI=0.73-3.07) tumors (p-heterogeneity=0.94).  
 
Breast cancer risk by grade and tumor size among women with BBD 
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While breast cancer risk associations for patient and histologic characteristics were generally 
consistent by tumor grade, we found suggestive evidence that higher levels of involution were inversely 
associated with reduced risk among well-differentiated tumors (complete vs no involution, OR (95%CI) = 
0.51 (0.29, 0.90), Supplemental Table 3); this association was not evident among moderately or poorly 
differentiated tumors; p-het=0.054. Associations for patient and histologic characteristics by tumor size 
(<20mm indicating small and >20mm larger tumors) are presented in Supplemental Table 4.  We did not 
observe any significant heterogeneity by tumor size, although associations of severity of BBD histology 
(P<0.0001) and presence of CCLs (P=0.038) with increased breast cancer risk were somewhat stronger 
among patients with smaller tumors. 
 
Breast cancer risk by menopausal status at BBD diagnosis and before and after 1993 
We performed additional analyses stratified by menopausal status using factors that have been 
significantly associated with breast cancer risk, in our study population (Table 3). The association of CCLs 
with elevated breast cancer risk was most apparent for postmenopausal women (OR=2.08, 95% CI=1.21, 
3.58); p-het=0.09.   
We did not find evidence of heterogeneity in risk factor associations before and after 1993 when 
75% of women over 45 had had a screening mammogram (Supplemental Table 5), suggesting 
associations are robust 
 
Discussion 
There are few BBD cohort studies with comprehensive follow-up and detailed characteristics on 
subsequently diagnosed invasive tumors. Among a large, well-characterized cohort of patients diagnosed 
with BBD, we expanded upon previous analyses in this population [7],[8] that  evaluated associations of 
well-established breast cancer risk factors and BBD features with  breast cancer risk to determine herein if 
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there exists possible etiologic heterogeneity using tumor characteristic data obtained from the longstanding 
high quality Kaiser tumor cancer registry [16]. Determining risk associations by tumor subtypes has been 
increasingly recognized as an important area of research [20, 21]. We comprehensively analyzed 
histopathologic features of the BBD biopsy and clinicopathologic characteristics of the breast tumors that 
developed subsequent to BBD diagnosis.  We found that most breast cancers diagnosed among BBD 
patients within this general community healthcare plan were the low stage, ER-positive tumors that tend to 
be highly responsive to treatments. Compared with patients with non-proliferative BBD, those with 
proliferative BBD with atypia had an over five-fold increased risk of ER-positive breast cancer. Our 
analyses provided limited evidence for heterogeneity in risk factor associations that we evaluated by tumor 
characteristics.  Importantly, histology and presence of CCLs at the time of BBD were independently 
associated with subsequent breast cancer risk irrespective of ER status, or tumor size or grade. These data 
provide further support for CCLs as a breast cancer risk factor, especially for postmenopausal BBD 
patients.  
 
Patient characteristics and breast cancer risk  
We extended prior findings by evaluating etiologic heterogeneity for risk factors thought to be most 
relevant for subsequent risk among BBD patients. Consistent with multiple studies of women diagnosed 
with sporadic breast cancer [9-12] and with the Mayo Clinic BBD cohort [6], we observed that parity/age 
at first birth was significantly associated with future breast cancer risk. Also consistent with limited data 
from other BBD cohorts [6], we found that history of bilateral oophorectomy was associated with reduced 
breast cancer risk, whereas positive family history of breast cancer in a 1st degree relative tended to be 
associated with increased breast cancer risk. We were able to further evaluate potential etiologic 
heterogeneity in risk associations, because our BBD study is nested within a single, large, well-defined 
population with access to healthcare and with a long-standing tumor tissue registry that has collected data 
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since the 1960’s. Although the number of ER-negative tumors was limited, we confirmed patterns of 
association by ER status that have also been observed among women diagnosed with sporadic breast 
cancers [9-12]. For example, early age at first birth showed an inverse association with ER-positive tumors 
suggesting that reproductive risk factor associations among BBD patients may be similar to those observed 
in the general population.  
ADH 
It has long been established that ADH is a high-risk precursor lesion, conferring a 4-5-fold increase 
in risk of breast cancer development [3]. Indeed, our analysis of BBD patients showed that compared to 
non-proliferative lesions, a diagnosis of ADH was associated with over 5-fold increased breast cancer risk; 
however, this association was limited to risk of ER-positive breast cancer, with little or no risk observed for 
ER-negative disease. Limited data from cohorts have reported on the relation of ADH by hormone receptor 
subtype. Consistent with our results, a previous population-based case-control study, CASH, found that 
history of any benign breast disease was associated only with increased risk of ER-positive luminal A 
tumors (OR = 1.89, 95% CI 1.43-2.50) [22]. These findings support the hypothesis that benign lesions are 
more likely to be hormone receptor positive with less genomic instability [23-26]. Moreover, the finding 
that ADH might be more relevant for ER-positive breast cancer risk is also consistent with hormonal 
chemoprevention trials which show a significant reduction in risk in women diagnosed with ADH [5, 27]. 
 
Proliferative BBD without atypia  
Proliferative disease without atypia is a conglomerate of multiple different pathologies. Radial scars 
are proliferative lesions that visually appear similar to tumors on mammograms. Pathologically, they are 
associated with epithelial elements and/or other proliferative lesions such as sclerosing adenosis. Recent 
analyses in two Swedish cohorts recruited through mammography screening programs from 2001-2013 
with over 75,000 subjects did not find any significant heterogeneity when evaluating the associations of 
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non-proliferative or proliferative BBD lesions with risk of molecularly defined subtypes of breast cancer; 
however, a limitation in this study was that there was no separation of proliferative lesions with or without 
atypia [28]. Our analysis using the Page classification of BBD histology showed that PDWA was 
associated with increased risk of both ER+ and ER- disease. This is consistent with the hypothesis that 
these lesions serve as precursor lesions in the natural history of breast cancer [3]. The Nurses’ Health Study 
and the Mayo BBD study showed radial scars to be one of the PDWA lesions associated with breast cancer 
risk, with an almost 2-fold increased risk [6, 29]. The Nurses’ Health study cohorts showed an independent 
association after adjusting for BBD histology. After restricting analyses to BBD patients with proliferative 
disease, we did not find a significant increase in risk associated with sclerosing adenosis or radial scar.  
Reasons for these discrepancies could be differences in the study populations as the calendar periods for all 
three of the cohorts overlap; the Nurses BBD cohort were women who reported a first diagnosis of BBD 
between 1976-1998; the Mayo BBD cohort is a hospital-based referral center that may see more high-risk 
women but with a similar calendar period to our study with BBD diagnoses occurring between 1967-2001. 
As our study was embedded in a health care organization where the women are actively followed and had 
access to mammography screening, breast cancers detected in our study may be found earlier than in other 
cohorts which makes direct comparisons difficult.  
 
Columnar cell lesions  
While its generally accepted that ADH, lobular neoplasia and ductal carcinoma in situ (DCIS) are 
precursor lesions for breast cancer [30, 31],  evidence is accumulating that CCLs may also be a precursors, 
although conveying lower risk particularly among populations with access to mammography screening  
[32-34]. Our data support CCLs as a common risk factor for both ER-positive and ER-negative breast 
cancers with relative risk estimates of around 1.5 after accounting for BBD histology, for both tumor types. 
Molecular analyses of CCLs suggest that some alterations occur early and mimic those observed in 
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coincident established precursor lesions such as DCIS [3, 8, 23, 33, 35-42]. There are three other studies 
that have evaluated CCLs in BBD cohorts, Nashville, Nurses, and Mayo and our data are consistent with 
the findings of all three [23, 35, 36, 40]. Only the Nurses BBD cohort obtained tumor characteristics on 
cases and also did not find any significant differences by ER status or grade, which is consistent with our 
data. Current management of CCL, according to the Mayo Clinic review, suggests that these patients 
should be managed with annual clinical breast exams and mammography [3]. Our data suggest CCL might 




Reduced lobular involution has been previously shown to be a significant factor associated with 
elevated breast cancer risk among women with BBD [19, 43, 44].  In the present study, we found that 
involution was weakly inversely related with breast cancer risk for ER+ disease. Further, higher levels of 
lobular involution were inversely and significantly associated with risk for well-differentiated tumors, a 
finding which was not observed for moderately or poorly differentiated tumors. As there were relatively 
few hormone negative cases in this population, we had limited power to test for differences by ER status. A 
limitation of this study is the absence of data on menopausal hormone therapy (MHT) use after BBD 
diagnoses, as MHT uptake was rising at the same time that mammography screening was increasingly 
being adopted [16]. Given previous studies showing that recent MHT use reduces involution levels among 
current but not former users [45], we hypothesize that MHT use post BBD diagnosis may be an 
unmeasured negative confounder attenuating involution associations towards the null.  Overall, it is unclear 
whether screening practices, unmeasured MHT use, or/and both might confound observed associations 
with involution. Additional contemporary studies in other populations with managed health care might help 
clarify the relationship of involution with future breast cancer risk.   
 16 
This is a unique cohort of women enrolled in a general community health care plan, providing the 
population access to screening and preventative services that may not be typical for other subsets of the US 
population. It is not currently known whether women with BBD are followed and screened more closely 
compared to women without BBD diagnoses. Current data from a study of over 42,000 screened women in 
Spain found that women with a previous benign breast disease diagnosis had a higher cumulative risk of 
screen-detected cancer and interval cancers, consistent with data supporting BBD as a risk factor for breast 
cancer regardless of mode of detection [46]. Whether women with BBD in our cohort are more likely than 
the general population to participate in screening is not known but could be the subject of future research.  
 
Strengths/Limitations 
A limitation of our study is that risk estimates are based on a BBD patient population diagnosed on 
excisional biopsies during a calendar period spanning the adoption of widespread mammography 
screening, which became more commonplace in KPNW around 1993; thus, associations may not be 
reflective of BBD diagnosed in more recent years.  Since 1995, advances in breast imaging technologies 
have resulted in a shift in diagnostic biopsy procedures to core needle biopsies, which currently comprise 
about 80% of biopsies in the US [47]. Based on data from the US Breast Cancer Surveillance Consortium, 
risks associated with high-risk ADH lesions on excisional biopsy were lower when diagnosed via core 
biopsy (6.7% vs 5.0%), perhaps reflecting the size of the ADH focus [47]. Another limitation as noted 
earlier, was the absence of risk factor data after BBD diagnosis and in particular on MHT use, which has 
been noted to be prevalent at KPNW at this time [16] and could have biased the results, especially with 
respect to the findings for involution. The small number of patients with ER-negative breast cancers is 
another limitation. Our study had multiple strengths: it was a nested-case control study embedded within a 
large, well-characterized BBD cohort with lengthy follow-up and access to archival BBD tissues and well-
established detailed tumor registry data, the latter aspect allowing us to provide one of the most detailed 
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analyses to date of tumor characteristics of breast cancers diagnosed among the vast majority of patients. 
Moreover, because we studied women in a healthcare management organization we could also evaluate 
temporal changes in access to mammography screening, data that are limited in other cohorts. 
 
Summary and conclusions 
Within this BBD cohort, the largest to date with longitudinal follow up, we provide breast cancer 
risk factor associations within an HMO patient population [7]. Our data provide further evidence that 
PDWA is associated with both ER-positive and ER-negative disease. Further, we show CCLs are 
associated with moderate increases in breast cancer risk, independent of BBD histology, and irrespective of 
ER status, in agreement with previous studies. Given the predominance of low-stage ER-positive tumors 
that developed among this cohort, our findings suggest that invasive cancers that develop subsequent to a 
BBD diagnosis are likely highly treatable with low mortality. Histologic evaluation of BBD biopsies is a 
promising avenue for the identification of new risk factors for different molecular subtypes of breast cancer 
and could inform the natural history of disease; however, given complex relationships between screening 
and diagnosis, along with secular changes in risk factor prevalence, contemporary prospective studies are 
needed to clarify the relationships of factors that may influence progression of BBD to cancer.  
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